4891.T Stock - TMS Co., Ltd.
Unlock GoAI Insights for 4891.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $1.95B | N/A |
| Gross Profit | $-3,709,000 | $-6,950,000 | $-6,596,000 | $1.95B | $-4,089,000 |
| Gross Margin | N/A | N/A | N/A | 100.0% | N/A |
| Operating Income | $-907,791,000 | $-943,253,000 | $-520,149,000 | $1.14B | $-721,156,000 |
| Net Income | $-660,548,000 | $-960,040,000 | $-860,925,000 | $1.08B | $-722,932,000 |
| Net Margin | N/A | N/A | N/A | 55.3% | N/A |
| EPS | $-16.38 | $-26.02 | $-25.28 | $53.36 | $-20.89 |
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the drug candidate compounds as novel drugs, as well as a joint research agreement with Teikyo University to identify biomarkers for renal function and a strategic alliance with Ji Xing Pharmaceuticals Limited. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
Visit WebsiteEarnings History & Surprises
4891.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 15, 2025 | — | $-4.36 | — | — |
Q3 2025 | Jul 15, 2025 | — | $-6.75 | — | — |
Q2 2025 | Apr 11, 2025 | — | $0.55 | — | — |
Q1 2025 | Jan 14, 2025 | — | $-5.08 | — | — |
Q4 2024 | Oct 15, 2024 | — | $-5.71 | — | — |
Q3 2024 | Jul 12, 2024 | — | $-6.14 | — | — |
Q2 2024 | Apr 12, 2024 | $13.23 | $-10.46 | -179.1% | ✗ MISS |
Q4 2023 | Nov 30, 2023 | — | $-6.06 | — | — |
Q3 2023 | Aug 31, 2023 | — | $-5.30 | — | — |
Q2 2023 | May 31, 2023 | — | $-4.07 | — | — |
Q1 2023 | Feb 28, 2023 | — | $-2.95 | — | — |
Q4 2022 | Nov 30, 2022 | — | $-8.51 | — | — |
Q3 2022 | Aug 31, 2022 | — | $-7.07 | — | — |
Latest News
Frequently Asked Questions about 4891.T
What is 4891.T's current stock price?
What is the analyst price target for 4891.T?
What sector is TMS Co., Ltd. in?
What is 4891.T's market cap?
Does 4891.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4891.T for comparison